drugset / Trial / NCT01193361
Ph IIA Study (SOC +/- NS5B)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
At least 1 dose of BMS-791325 can be identified which is safe, well tolerated, and efficacious when combined with peg-interferon alfa-2a (pegIFNα-2a)/ribavirin (RBV) for the treatment of treatment-naïve, chronically-infected hepatitis C virus (HCV) genotype 1 subjects
Timeline
- Start
- 2010-10
- Primary completion
- 2011-06
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Beclabuvir | Small molecule | 75 mg | Oral |
| Subject | Beclabuvir | Small molecule | 150 mg | Oral |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Background | Ribavirin | Small molecule | 1000 mg | Oral |
| Background | Ribavirin | Small molecule | 1200 mg | Oral |